Onconova Therapeutics Inc... (ONTX)
NASDAQ: ONTX
· Real-Time Price · USD
1.00
0.00 (0.00%)
At close: Apr 02, 2024, 10:00 PM
Onconova Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 2.73B | 57M | 226B | 57K | 57M | 56K | 56K | 57K | 57K | 56K | 56K | 57K | 57K | 56K | 56K | 57K | 57K | 56K |
Cost of Revenue | n/a | n/a | 117,464B | n/a | n/a | n/a | 12K | 5K | 4K | 3K | 4K | 3K | 4K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | -117,238B | n/a | n/a | 56K | 44K | 52K | 53K | 53K | 52K | 54K | 53K | 56K | 56K | 57K | 57K | 56K |
Operating Income | -1.25B | -5.2B | -142,374B | 123.34B | -123.35B | -5.21M | -4.46M | -5.09M | -4.61M | -6.14M | -5.73M | -5.64M | -4.12M | -4.13M | -3.76M | -3.99M | -4.64M | -4.1M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 651K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -915M | 21.49B | -166,523B | 123.13B | -123.14B | -4.98M | -4.18M | -4.74M | -4.25M | -5.78M | -5.42M | -5.4M | -4.02M | -4.12M | -3.76M | -3.45M | -4.23M | -4.71M |
Net Income | -915M | 21.49B | -166,523B | -8.47M | -123.14B | -4.98M | -4.18M | -4.74M | -4.25M | -5.41M | -5M | -5.16M | -3.93M | -4.11M | -3.76M | -3.45M | -4.23M | -4.71M |
Selling & General & Admin | 1.69B | 2.75B | 12,289B | 3.48M | 1.98B | 3.36M | 2.08M | 2.69M | 2.21M | 2.11M | 2.02M | 2.1M | 2.14M | 2.19M | 2.07M | 2.28M | 2.85M | 2.22M |
Research & Development | 2.29B | 2.51B | 12,847B | 5.11M | 3.96B | 1.91M | 2.43M | 2.46M | 2.46M | 4.08M | 3.77M | 3.59M | 2.04M | 2M | 1.75M | 1.76M | 1.85M | 1.94M |
Other Expenses | n/a | n/a | -857K | n/a | 117.46B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 10K | -1K | 7K | -13K | 19K |
Operating Expenses | 3.98B | 5.26B | 25,136B | 8.59M | 123.41B | 5.27M | 4.52M | 5.15M | 4.67M | 6.19M | 5.79M | 5.7M | 4.18M | 4.19M | 3.82M | 4.05M | 4.7M | 4.15M |
Interest Expense | n/a | n/a | -362K | n/a | n/a | n/a | 362K | n/a | n/a | n/a | 102K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | n/a | 142,600B | n/a | n/a | 5.27M | 4.52M | 5.15M | 4.67M | 6.19M | 5.79M | 5.7M | 4.18M | 4.19M | 3.82M | 4.05M | 4.7M | 4.15M |
Income Tax Expense | n/a | n/a | -366K | n/a | n/a | n/a | n/a | n/a | -4K | -362K | -420K | -243K | -96K | -10K | -4K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 58.21M | 15.53M | 15.53M | 20.42M | 25.31M | 21.04M | 20.99M | 21M | 20.98M | 20.96M | 20.93M | 20.92M | 20.9M | 20.61M | 15.98M | 15.98M | 15.67M | 14.62M |
Shares Outstanding (Diluted) | 58.21M | 15.53M | 15.53M | 20.42M | 25.31M | 21.04M | 20.99M | 21M | 20.98M | 20.96M | 20.93M | 20.92M | 20.9M | 20.9M | 15.98M | 15.98M | 15.78M | 14.62M |
EPS (Basic) | -0.11 | 308.50 | -10.72M | -8.81 | -4.87K | -0.24 | -0.2 | -0.23 | -0.2 | -0.26 | -0.24 | -0.25 | -0.19 | -0.2 | -0.24 | -0.22 | -0.27 | -0.32 |
EPS (Diluted) | -0.11 | 1.38K | -10.72M | -0.42 | -4.87K | -0.24 | -0.2 | -0.23 | -0.2 | -0.26 | -0.24 | -0.25 | -0.19 | -0.2 | -0.24 | -0.22 | -0.27 | -0.32 |
EBITDA | -1.25B | -5.2B | -166,523B | -8.54M | -123.35B | -5.21M | -4.46M | -5.08M | -4.61M | -6.13M | -5.73M | -5.64M | -4.12M | -4.13M | -3.76M | -4.52M | -5.07M | -3.46M |
EBIT | n/a | n/a | 3.82M | n/a | n/a | -5.21M | -3.82M | -5.09M | -4.61M | -6.14M | -5.32M | -5.64M | -4.03M | -4.13M | -3.76M | n/a | n/a | n/a |
Depreciation & Amortization | n/a | n/a | -13K | n/a | n/a | 4K | 4K | 5K | 4K | 3K | 4K | 3K | 4K | 3K | 4K | 3K | 4K | 3K |